Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Upgraded by TD Cowen

TD Cowen upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a buy rating in a report issued on Tuesday, Marketbeat.com reports. They currently have $175.00 price target on the biotechnology company’s stock, up from their previous price target of $156.00.

A number of other equities analysts also recently commented on ASND. Stifel Nicolaus initiated coverage on Ascendis Pharma A/S in a report on Friday, May 31st. They issued a buy rating and a $200.00 price objective on the stock. Cantor Fitzgerald restated an overweight rating and issued a $173.00 price target on shares of Ascendis Pharma A/S in a report on Wednesday, May 15th. StockNews.com upgraded shares of Ascendis Pharma A/S from a sell rating to a hold rating in a research note on Thursday, May 23rd. Wells Fargo & Company raised their target price on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an overweight rating in a research note on Friday, May 3rd. Finally, JPMorgan Chase & Co. lifted their target price on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an overweight rating in a report on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $179.00.

Ascendis Pharma A/S Stock Performance

ASND opened at $136.38 on Tuesday. Ascendis Pharma A/S has a 1 year low of $85.29 and a 1 year high of $161.00. The company’s 50 day simple moving average is $132.36 and its 200 day simple moving average is $137.56. The stock has a market capitalization of $7.94 billion, a PE ratio of -14.19 and a beta of 0.59.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($2.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.91). The company had revenue of $103.11 million during the quarter, compared to analyst estimates of $85.72 million. Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -5.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently made changes to their positions in the business. Westfield Capital Management Co. LP grew its holdings in Ascendis Pharma A/S by 1.1% during the 1st quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock worth $616,050,000 after acquiring an additional 44,580 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 5.6% during the first quarter. Avoro Capital Advisors LLC now owns 3,966,666 shares of the biotechnology company’s stock worth $599,641,000 after purchasing an additional 211,111 shares during the last quarter. Capital International Investors grew its stake in Ascendis Pharma A/S by 0.5% in the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after purchasing an additional 10,044 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in Ascendis Pharma A/S by 20.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock valued at $191,346,000 after buying an additional 254,749 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.